UniProt P53355 · PDB · AlphaFold · Substrate: ZIPtide · Clone: full catalytic (aa 1-363)medium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Fedratinib | 97.3% | 2.6% | 96.21 | 0.576 |
| 2 | Pacritinib | 93.6% | 6.4% | 88.64 | 0.452 |
| 3 | Alectinib | 89.5% | 10.5% | 95.49 | 0.651 |
| 4 | Baricitinib | 81.9% | 18.1% | 97.99 | 0.616 |
| 5 | Brigatinib | 62.6% | 37.4% | 82.96 | 0.513 |
| 6 | Sunitinib | 49.0% | 51.0% | 91.73 | 0.524 |
| 7 | Gilteritinib | 48.7% | 51.3% | 88.97 | 0.506 |
| 8 | Defactinib | 47.7% | 52.3% | 92.68 | 0.450 |
| 9 | Selpercatinib | 41.9% | 58.1% | 96.72 | 0.635 |
| 10 | Pralsetinib | 36.4% | 63.6% | 93.43 | 0.643 |
| 11 | Ruxolitinib | 34.1% | 65.9% | 98.25 | 0.592 |
| 12 | Neratinib | 30.6% | 69.4% | 93.18 | 0.597 |
| 13 | Midostaurin | 27.2% | 72.8% | 78.64 | 0.500 |
| 14 | Abemaciclib | 26.4% | 73.6% | 91.48 | 0.563 |
| 15 | Osimertinib | 22.3% | 77.7% | 97.24 | 0.733 |
| 16 | Lazertinib | 21.0% | 79.0% | 97.47 | 0.674 |
| 17 | Pirtobrutinib | 20.7% | 79.3% | 99.49 | 0.656 |
| 18 | Upadacitinib | 18.8% | 81.2% | 97.98 | 0.663 |
| 19 | Palbociclib | 18.3% | 81.7% | 98.75 | 0.673 |
| 20 | Capivasertib | 17.7% | 82.3% | 96.48 | 0.644 |
Paralog block
DAPK1, DAPK2
EMT expression
- Mesenchymal log2(TPM+1): 2.42
- Epithelial log2(TPM+1): 2.63
- Fold change: -0.21
- Status: No significant change
High-confidence drugs
- Fedratinib — inh 97.3% · KISS 39.16
- Alectinib — inh 89.5% · KISS 31.08
- Baricitinib — inh 81.9% · KISS 27.22
Selectivity landscape vs inhibition on DAPK1
Each point is one of the 92 approved drugs; color = inhibition % on DAPK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…